Rituximab impedes natural killer (NK) cells function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) patients: A pilot in vitro investigation outlines the toxicological effect Rituximab has on the…
potential for the better therapeutic outcome and less side effects like anti CD 20, rituximab. To assess rituximab's efficacy in inducing renal remission in a patient with lupus nephritis ... nine subjects with…
Background: Since the introduction of rituximab (R), outcome of diffuse large B cell lymphoma (DLBCL) has significantly improved. R-CHOP (C: Cyclophosphamide, H: Adriamycin, O: Vincristine and P: Prednisolone
patients who failed to achieve adequate response to steroids were randomized to receive rituximab or placebo plus standards of care (Ghanima et al. Lancet 2015; 385:1653-61). Study ... follow-up of 18 months. Apart from…
Rituximab has been widely used in clinical practice for the treatment of B-cell malignancies, but the majority of patients retreated with rituximab will eventually relapse with variable degrees ... resistant disease…
Rituximab is an antineoplastic agent. It is a humanized chimeric CD20 directed monoclonal antibody. Hypokalemia is defined as a serum potassium level of less than. Saudi Food and Drug authority ... SFDA) has detected a…
autologous transplantation and induction chemotherapy that includes high-dose cytarabine. The introduction of rituximab and bendamustine, however, has led to the improvement of prognosis of diffuse large B-Cell lymphoma…
adverse effects but are expensive. Aim: To compare the cost of DCP & low-dose Rituximab therapy in pemphigus in a government tertiary hospital. Methods: We calculated the cost ... therapy (3 phases) and low dose…
standard of care, however there are refractory cases of TTP which require further managements. Rituximab is used as salvage treatment for refractory TTP. We report here two difficult cases ... refractory TTP responded…
Rituximab (anti-CD20 antibody) has been approved as a treatment for B-cell associated hematological disorders. CD20 expression and its complement regulatory proteins and membrane binding structures play a crucial…
phenomenon in the process of invasion and metastasis of many malignancies such as lymphoma. Rituximab is the first monoclonal antibody to be approved for the treatment of lymphoma. Epitope complex ... rituximab has been…
high relapse rate, and some patients do not respond satisfactory to this treatment. Rituximab is a chimeric monoclonal antibody directed against CD20, a cell surface antigen expressed almost exclusively ... cells of…
With the help of retrospective analysis the researchers tried to evaluate the effectiveness of rituximab in preventing the acquired TTP in China. Out of 27 patients with acquired TTP that ... have registered from 2006…
slow growth and high initial response rate, many patients experience disease progression and relapse. Rituximab has significantly improved the outcomes of patients with B-cell lymphomas, as well ... randomized studies…
Rituximab is a chimeric mouse/human monoclonal antibody that is indicated primarily for the treatment of Non-Hodgkin’s lymphoma (NHL). Rituximab cell destruction activity is mediated via binding ... reason for this…
Hodgkin´s lymphoma (NHL) is an increasing disease across the board. Intravenous rituximab was first approved as NHL treatment in 1997. Normally, rituximab intravenous infusion takes more than three hours ... home. The…
Objective: To study the efficacy of rituximab in children with focal sclerosing glomerulonephritis (FSGS). Case Report: Before treatment, blood biochemistry, hepatic and renal function, differential white cell counts…
inflammatory disease affecting the central nervous system and leading to neurological defects. Rituximab is a medication that is administered intravenously for treating MS. The present study examined the one-year…
evaluated the response and toxicity, after long-term follow up of Iodine-131 rituximab radioimmunotherapy in patients with follicular lymphoma under the routine clinical care of a single hematologist over ... period of…
evaluate the effectiveness of rituximab in conjunction with cyclosporine in managing refractory idiopathic thrombocytopenia. A retrospective analysis was performed on 210 adult individuals diagnosed with refractory…
idiopathic NA-SCAD (non-atherosclerotic spontaneous coronary artery dissection) occurring in a patient receiving rituximab chemotherapy for stable Stage IV follicular lymphoma. This patient experienced typical angina…
Purpose: Cy754 was combined with Rituximab to prepare a new receptor-targeted tracer for Sentinel Lymph Node (SLN). The appropriate combination ratio of the tracer was identified, the biological property ... imaging…
this study was to investigate the impact of prior rituximab on the subsequent results of autologous stem cell transplantation (ASCT) for relapsed or primary refractory diffuse large B-cell lymphoma ... measure…
analyze the risk factor for infusion related reaction (IRR) due to the rituximab treatment in patients with B cell non-Hodgkin’s lymphoma. Methods: A retrospective analysis was conducted ... newly diagnosed B cell…
Rituximab is a chimeric monoclonal antibody to CD 20 antigen. It is commonly used in treatment of non-Hodgkin’s lymphoma & rheumatoid arthritis. Rituximab is also under investigation ... conditions including chronic…
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.